Clindamycin 1.2% | Tretinoin 0.03%

Route: Topical application to acne-affected areas of the face (or body as directed).

• Cleanse and gently dry the face before application.
• Apply a thin, even layer to the entire affected area once daily in the evening.
• Avoid the eyes, lips, nasal mucosa, and open lesions.
• Evening/nighttime application is preferred as tretinoin is photolabile and increases UV sensitivity.
• Use a pea-sized amount for the face; do not increase frequency to hasten results—increasing frequency primarily increases irritation.

Typically applied once daily in the evening to acne-affected areas. Prescriber determines frequency and duration:

• Initial treatment: once daily; may reduce to every other day or every third day if significant irritation occurs, increasing frequency as tolerance develops.
• Minimum 8–12 weeks of consistent use before clinical response is fully assessable.
• Long-term maintenance use may be appropriate once acne control is achieved.

• Clindamycin (1.2%): Binds the 50S ribosomal subunit of bacteria, blocking transpeptidation and elongation of the peptide chain; bacteriostatic at clinical concentrations against Cutibacterium acnes (formerly Propionibacterium acnes). Reduces follicular bacterial populations and decreases free fatty acid generation from sebum triglyceride hydrolysis, reducing inflammatory mediator load in the follicle.
• Tretinoin (0.03%): Retinoic acid receptor (RAR-α, -β, -γ) agonist; receptor-ligand complex activates retinoid hormone response elements in keratinocyte nuclei, normalizing follicular epithelial keratinization, reducing cohesion of corneocytes (promoting their shedding), inhibiting microcomedone formation, and increasing turnover of keratinized cells to expel comedone contents.

This combination is used for the treatment of mild to moderate acne vulgaris, particularly mixed inflammatory and comedonal acne. Clindamycin alone does not address the primary precursor lesion (microcomedone), whereas tretinoin does not have antibiotic activity. Together they address both pathogenic axes, and tretinoin enhances follicular penetration of clindamycin by normalizing the follicular epithelium.

Prescriber monitoring:

• Antibiotic resistance monitoring: topical clindamycin monotherapy is associated with development of clindamycin-resistant C. acnes; combination with tretinoin may reduce this risk. Avoid concurrent systemic and topical clindamycin use without indication.
• Assess for retinoid-related skin irritation (dryness, erythema, peeling) in the first 4–6 weeks.
• Advise use of non-comedogenic moisturizer and broad-spectrum sunscreen (SPF 30+).
• Tretinoin is teratogenic; confirm patients are not pregnant.

Contraindications:

• Pregnancy (tretinoin; avoid in women who are or may become pregnant)
• Hypersensitivity to clindamycin, lincomycin, or tretinoin
• History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (clindamycin)

Warnings & Precautions:

• Photosensitivity: Tretinoin significantly increases UV sensitivity; daily SPF 30+ sunscreen and sun avoidance are required.
• Retinoid irritation: Erythema, dryness, and peeling are expected initially; reduce frequency if severe.
• Antibiotic-associated diarrhea/colitis: Topical clindamycin has a very low risk of systemic antibiotic-associated colitis, but this has been reported; discontinue and evaluate if persistent diarrhea develops.
• Tretinoin teratogenicity: Advise pregnancy avoidance.

Drug Interactions:

• Topical agents containing alcohol or high concentrations of benzoyl peroxide, salicylic acid, or sulfur may cause excessive irritation when used concomitantly with tretinoin.
• Erythromycin: clindamycin and erythromycin are antagonistic in vitro; avoid concurrent use.

Common Side Effects: Application site dryness, erythema, burning, peeling, and pruritus (most common in the first 2–4 weeks); scaling; increased sensitivity to sun.

Store at controlled room temperature (20–25°C / 68–77°F). Protect from light and heat. Do not freeze. Tretinoin is sensitive to light; consider storing in a dark cabinet. Keep tightly sealed. Use before the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.

Why are clindamycin and tretinoin used together for acne?

Acne has two major pathogenic axes: abnormal follicular keratinization (causing comedones) and bacterial colonization by C. acnes (driving inflammation). Tretinoin normalizes follicular shedding and eliminates microcomedones (the precursor to all acne lesions), while clindamycin reduces the bacterial load and associated inflammation. Used together, they address both axes simultaneously for greater efficacy than either agent alone.

Should I use this morning or evening?

Evening only. Tretinoin is degraded by ultraviolet light and significantly increases photosensitivity. Applying it at night avoids sun exposure and minimizes photodegradation. Use a non-comedogenic broad-spectrum sunscreen (SPF 30+) during the day.

What should I expect in the first few weeks?

Initial retinoid irritation—redness, dryness, flaking, and occasional increased breakout—is normal in the first 2–4 weeks and reflects accelerated cell turnover. This typically resolves by week 4–6. If severe, notify your prescriber about reducing application frequency.

Is this product FDA-approved?

Clindamycin 1.2%/tretinoin 0.025% combination is commercially available as Veltin® and Ziana®. This compounded preparation at tretinoin 0.03% is a 503A preparation from Genesis Compounding for a specific patient, not an FDA-approved product at these exact concentrations.

How long until I see results?

Significant improvement typically requires 8–12 weeks of consistent nightly use. Acne therapy requires patience; do not stop using the medication if early results seem modest.